key: cord-0905261-kjeeovxu
authors: Mishra, Nawneet; Teyra, Joan; Boytz, Ruthmabel; Miersch, Shane; Merritt, Trudy N.; Cardarelli, Lia; Gorelik, Maryna; Mihalic, Filip; Jemth, Per; Davey, Robert; Sidhu, Sachdev S.; Leung, Daisy W.; Amarasinghe, Gaya K.
title: Development of monoclonal antibodies to detect for SARS-CoV-2 proteins
date: 2022-04-08
journal: J Mol Biol
DOI: 10.1016/j.jmb.2022.167583
sha: f0d7233f3ea9ea681cec57d585758760903d57e8
doc_id: 905261
cord_uid: kjeeovxu

The COVID-19 pandemic caused by SARS-CoV-2 infection has impacted the world economy and healthcare infrastructure. Key reagents with high specificity to SARS-CoV-2 proteins are currently lacking, which limits our ability to understand the pathophysiology of SARS-CoV-2 infections. To address this need, we initiated a series of studies to generate and develop highly specific antibodies against proteins from SARS-CoV-2 using an antibody engineering platform. These efforts resulted in 18 monoclonal antibodies against nine SARS-CoV-2 proteins. Here we report the characterization of several Abs, including those that recognize Nsp1, Nsp8, Nsp12, and Orf3b viral proteins. Our validation studies included evaluation for use of antibodies in ELISA, western blots, and immunofluorescence assays (IFA). We expect that availability of these antibodies will enhance our ability to further characterize of host-viral interactions, including specific roles played by viral proteins during infection, to acquire a better understanding of the pathophysiology of SARS-CoV-2 infections.

The SARS-CoV-2 pandemic that began in 2019 highlights the urgent need for the rapid development of reagents to better understand viral pathogenesis, host responses, and develop diagnostics. SARS-CoV-2 is a positive-sense, single-stranded RNA virus with a genome of approximately 30 kb. Two-thirds of the 5' end of the viral genome encode Nonstructural proteins (Nsp) as a polyprotein, which self-cleaves by viral proteases and contributes to virus replication [1] . For example, Nsp1 has a role in translational l shutdown and evasion of host immune response [2] , and Nsp12 is the RNA-dependent RNA polymerase, which is essential for virus replication [3] . The last one-third of the genome encodes the structural envelope (E), membrane (M), and nucleocapsid (N) proteins, in addition to the non-essential accessory proteins. Among them, N and S proteins have been the major focus for the development of effective therapeutics based on monoclonal antibodies (mAbs) that would neutralize viral infection [4] . While a range of immune sera-derived polyclonal antibodies (pAbs) are available against SARS-CoV-2, there are few monoclonal antibodies (mAbs) available against non-spike SARS-CoV-2 proteins (Table S1) . Polyclonal antibodies (pAbs) are heterogeneous mixtures of antibodies (Abs) that can recognize and bind to many different epitopes of a single antigen, but batch to batch inconsistency can complicate reproducibility, and the undefined nature of their many epitopes limits their use in detailed molecular characterization. In contrast, mAbs typically recognize only a single epitope and are an indispensable resource in the fields of immunology, biotechnology, biochemistry, and applied biology due to their homogeneity, specificity, and renewability [5] . The lack of mAbs for SARS-CoV-2 viral proteins constitute a major bottleneck in evaluating cellular responses to vaccines and therapeutics [6] [7] [8] [9] . Therefore, efforts towards the generation of mAb reagents targeting as many of the SARS-CoV-2 viral proteins are necessary.

Here, we report the generation, characterization, and optimization of Abs targeting nine different SARS-CoV-2 proteins, including structural, non-structural, and accessory proteins. For this, we expressed and purified 21 recombinant SARS-CoV-2 proteins, carried out antibody selections by phage display, and validated binding of the IgGs to their cognate target in vitro. Due to their critical function in multiple steps of viral pathogenesis and infection cycle, 18 mAbs against Nsp1, Nsp8, Nsp12 and Orf3b were further characterized for activity in western blot (WB) and immunofluorescence (IF) assays with SARS-CoV-2-infected cells. Overall, our data provides a strong foundation for using these synthetic antibodies to study different SARS-CoV-2 viral proteins and for the development of novel diagnostic assays for COVID-19.

SARS-CoV-2 proteins were expressed as glutathione S-transferase (GST) or maltosebinding protein (MBP) fusion proteins in BL21 (DE3) Escherichia coli cells (Novagen).

Protein expression was induced at an OD 600nm of 0.6 with 0.5 mM isopropyl-thiogalactopyranoside for 12-15 h at 18 °C. Cells were harvested, resuspended in lysis buffer containing 25 mM Tris (pH 7.5), 150 mM NaCl, 20 mM imidazole, and 5 mM 2mercaptoethanol, lysed using an EmulsiFlex-C5 homogenizer (Avestin) and clarified by centrifugation at 30,000×g at 4 °C for 40 min. MBP-fused proteins were purified using an MBPTrap HP column (GE Healthcare) and ion exchange chromatography. GST-fused proteins were purified using glutathione sepharose 4 Fast Flow media (GE Healthcare) according to the manufacturer's protocols and eluted in buffer containing 50 mM Tris pH 7.8, 300 mM NaCl, 5 mM DTT.

Fab-phage clones specific for the SARS-CoV-2 proteins (Table S2) were isolated from phage-displayed antibody libraries [10] by four consecutive rounds of binding selections with the SARS-CoV-2 proteins immobilized in microwell plates, as described [10] .

Individual colonies were isolated from E. coli infected with phage outputs from rounds 3 and 4, and about 48 Fab-phage clones were amplified per antigen. Antibody variable domains of the clones that bound to antigen in Fab-phage ELISA were sequenced by PCR amplification, and unique clones were selected.

To estimate affinities of individual antigen binding clones, a two-point competitive phage ELISA was performed as described [11] . Phage supernatants were diluted in PBT buffer 

For binding ELISA experiments, 384-well microplates were coated overnight at 4 °C with 2 μg/mL protein or GST/MHT control proteins in PBS pH 7.4. After coating, wells were blocked with 0.2% BSA in PBS for one hour and washed 4 times with 0.05% Tween in PBS (PT buffer). Serial dilutions of IgG diluted into PBT were transferred to antigencoated plates and incubated at room temperature for 30 min, washed with PBST four times and incubated for 30 min with anti--HRP antibody conjugate (1:7500 dilution in PBT), which were washed, developed, and read, as described above. To estimate EC 50 values, data were fit to standard four-parameter logistic equations using GraphPad Prism (GraphPad Software, La Jolla, CA).

To determine binding kinetic parameters of IgGs for SARS-CoV2 proteins, BLI experiments were performed on an Octet HTX instrument (Sartorius) at 1000 rpm and 25 °C. All proteins were diluted in PBS containing 1% BSA and 0.05% Tween 20. 2-20 g/mL of SARS-CoV2 antigens or unrelated protein with similar size were first covalently captured on AR2G biosensors (Sartorius, 18-5092) by amine-reactive coupling chemistry, and unbound reactive N-hydroxysulfosuccinimide (NHS) esters on the biosensors were quenched for 600 s by 1M ethanolamine (pH 8.5). After equilibrating with assay buffer, the antigen-coated sensors were dipped for 600 s into wells containing serial 3-fold dilutions of IgGs and subsequently were transferred back into assay buffer for 600 s of dissociation. Binding response data were reference subtracted and were globally fitted with 1:1 binding model using ForteBio's Data Analysis software 9.0. (Figure 1, Table S2 ). For each antigen, 48 Fab-phage clones from selection outputs were screened by ELISA to compare binding to the cognate immobilized SARS-CoV-2 protein along with several negative control proteins (maltose binding protein (MBP), glutathione S-transferase (GST), and native bovine serum albumin (BSA), Figure   1B ). Unique Fab clones that bound specifically to corresponding SARS-CoV-2 proteins were identified by DNA sequencing of the complementarity-determining regions (CDRs) from the variable chains.

To prioritize our efforts on clones that bound more tightly to the target, we carried out a two-point competitive ELISA [11] , in which positive Fab-phage clones were pre-incubated with their cognate soluble antigen. Uncomplexed Fab-phage were then captured by immobilized antigen and the phage-binding signal compared to the phage-binding signal in the absence of soluble antigen ( Figure 1B) . Smaller ratios are indicative of higher affinity due to increased Fab-phage binding to solution-phase antigen, and consequently, less captured by the immobilized antigen. For each SARS-CoV-2 protein, clones that exhibited the lowest binding ratios in the two-point competitive assay (indicating tight binding to soluble protein) were selected for further characterization (Figure 1B) . In addition, to obtain clones targeting distinct SARS-CoV-2 epitopes on the same protein, selections were carried out against five domains of Nsp3, including domains 3a, 3b, 3c, 3d and 3e (Table S2) . This resulted in the isolation of Fab-phage clones that bound specifically to epitopes located in domains 3a and 3c (Table S2) . For Nsp1 and N proteins, selections were carried out against the full-length (FL) proteins, and isolated Fab-phage clones were then evaluated against the FL, N-terminal (NTD) and C-terminal (CTD) domains by ELISA enabling identification of Fab-phage clones binding the NTD and CTD epitopes of both proteins (Figure 1C and 1D, respectively) . Together, the competitive assay and the epitope mapping results obtained with Fab-phages were used to prioritize a total of 18 clones that bound to 9 SARS-CoV-2 proteins for sub-cloning, purification and functional characterization of the full-length IgG1 format (Figure 2A) .

To estimate affinities, ELISAs were performed to assess the binding of serial dilutions of IgGs to immobilized SARS-CoV-2 protein, and revealed that most of the IgGs bound with EC 50 values in the single-digit nanomolar range (Figure 1C, S1) , except for 16485, 16658, and 16684 IgGs, which bound at 19, 130 and 19 nM to N, Nsp7, and Nsp15, respectively.

To characterize affinities more quantitatively, binding was also assessed by biolayer interferometry (BLI). For this, purified IgG antibodies were captured on an anti-human Fc capture biosensor (AHC) and the binding kinetics were evaluated with soluble SARS-CoV-2 protein. The majority of the IgGs exhibited sub-nanomolar K D values, in close accord with the EC 50 values measured by ELISA (Figure 1C, S1) . Unexpectedly, we could not obtain binding signals for 16658 or 16684 IgGs to Nsp7 or Nsp15, respectively, and 15887 IgG bound much more weakly to Orf3b than shown by ELISA. We attribute these problems to the varying immobilization strategies which might differentially present the epitope of the antigen, and in these cases, alter binding.

To further characterize these mAbs, we focused on the IgGs binding to the key viral proteins Nsp1, Nsp8, Nsp12 and Orf3b for their direct involvement into host translation shutdown [6] , viral replication [3, 12] and immune antagonism [13] . We performed western blot (WB) analysis to further evaluate the ability of the mAbs to specifically detect each respective protein. Our results show that these mAbs can be used to detect denatured protein by WB (Figure 2C-F Each of these mAbs showed no reactivity to a negative control maltose binding protein (MBP), thus confirming their specificity.

To assess the suitability of our synthetic antibodies in immunofluorescence (IF) assays, VeroE6 cells were grown in 8-well µ-slides and infected with SARS-CoV-2 (MOI 0.2) prior to immunolabeling with expressed IgGs as the primary antibody. A commercially available rabbit antibody to SARS-CoV-2 N protein was used as a control and marker for virus infection [14, 15] . When acquiring images for each mAb, we set the laser intensity and exposure such that there was no signal in the 488 channels (channel containing primary antibody) for uninfected cells and maintained these settings when imaging infected cells. (Figure 2A) , our results showed a punctate pattern within the nucleus or directly on its edge [16] . We also observed a similar punctate staining for Nsp12 and Orf3b largely in the perinuclear region of infected cells. However, we were unable to visualize targets using the antibodies against Nsp8 (15525), which did not result in a detectable stain above background (Figure 3A) . The fact that IgG binds to Nsp8 in vitro, suggests that the IgG epitopes may be inaccessible in the cellular environment. This may be due to the fact that Nsp8 is a small protein (198 amino acids) and that functions as a stable heterocomplex with Nsp7 and Nsp12 required for replication [17, 18] , creating steric hindrance in the IgG recognition in infected cells. Overall, our results validate the use of antibodies 15887, 15884, 15497, and 15498 in IF assays and suitability for characterization of the cellular localization of SARS-CoV-2 viral proteins.

Moreover, sub-cellular localization patterns of Orf3b, and Nsp12 could be visualized by immunofluorescence. In N-stained cells, we found expression of Orf3b in N-expressing cells, but also cells lacking N expression, which suggests that Orf3b is expressed at the early stage of SARS-CoV-2 infection, or it is translocating to neighboring cells ( Figure   3A ). Orf3b exhibited a punctate staining pattern within the cytoplasm of infected cells ( Figure 3B, right panel) , which is consistent with previous studies showing SARS-CoV-2

Orf3b localization in the cytosol, where it suppresses IFN-I activation [13] . Unlike Orf3b, Nsp12 appeared as clusters of puncta surrounded by a faint, diffuse background mostly localized to the perinuclear region of infected cells (Figure 3B, left panel) . We noticed that the puncta were distributed across multiple z-planes, which suggests a 3D structure.

To better visualize this, we took z-stacks at 100x, followed by image deconvolution, and generated a maximum-intensity projection image (Figure 3B, middle panel) . This structure and localization differ from the cytosolic localization observed by others upon Nsp12 overexpression [19] . In this regard, we observe puncta-like structures or inclusion bodies. Furthermore, N staining shows that N protein is not necessarily highly expressed at the time as the other SARS-CoV-2 proteins and cells with high levels of N staining lacked detectable Nsp12 expression, whereas Nsp12, which is the essential component of the replication machinery, appears to be detected before an abundance of N protein.

Thus, these sites may be indicative of the replication complexes in SARS-CoV-2 infected cells, which are found in both N-expressing and non-expressing cells, like Orf3b ( Figure   3A ). Overall, our results validate the use of antibodies 15884 and 15887 in IF procedures and provide support for their use in studying sub-cellular locations of SARS-CoV-2 viral proteins. Further optimization will be warranted to fully understand the structures observed here.

As the COVID-19 pandemic progresses into the 3 rd year, there are many remaining questions surrounding SARS-CoV-2 biology. Here we describe a number of validated critical reagents that provide new tools to better understand viral infection and host responses ( Table S1 ). In this report, we describe our efforts to develop 18 monoclonal IgGs binding specifically to 9 different SARS-CoV2 proteins at sub-nanomolar affinities.

We validated and further characterized several mAbs in vitro, further demonstrating the potential impact of these reagents. For key targets involved in host response modulation and viral replication, the suitability of these antibodies in WB and IF applications were demonstrated, thus providing validation of the utility of these reagents. IgGs binding to two non-overlapping epitopes for Nsp1, Nsp3 and N proteins were obtained by tailored selections against individual domains. Insofar as pairs of antibodies targeting distinct epitopes have utility in diagnostic and quantitative assays [21] , this basic characterization may help to fast-track applications development or provide tools to evaluate the differential roles of the distinct regions of each of these multi-domain, multi-functional viral proteins. These reagents also have potential utility for a number of assays, such as flow cytometry, immunofluorescence staining, coimmunoprecipitation assays, and for biochemical and structural characterization of the proteins. Our efforts further illustrate the facile implementation of the phage display platform to generate critical reagents to study SARS-CoV-2 proteins and their host interactions leading to a better mechanistic understanding at the host-pathogen interface. Table S2 . SARS-CoV-2 proteins used as antigens for Fab-phage selections and binding characterization, including construct boundaries, tags, and the laboratory that generated them.

Novel coronavirus disease (COVID-19) pandemic: A recent mini review

Evasion of Type I Interferon by SARS-CoV-2

Transient and stabilized complexes of Nsp7, Nsp8, and Nsp12 in SARS-CoV-2 replication

Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs

The ABCs of finding a good antibody: How to find a good antibody, validate it, and publish meaningful data

SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms

Benefits And Risks Of Administering Monoclonal Antibody Therapy For Coronavirus (COVID-19)

Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression

Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins

CDR-H3 diversity is not required for antigen recognition by synthetic antibodies

The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies

Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex

Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

The SARS-CoV nucleocapsid protein: a protein with multifarious activities

The coding capacity of SARS-CoV-2

Structural Basis and Function of the N Terminus of SARS-CoV-2 Nonstructural Protein 1

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Architecture of a SARS-CoV-2 mini replication and transcription complex

SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation

Modulation of the immune response by Middle East respiratory syndrome coronavirus

Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

An atomistic model of the coronavirus replication-transcription complex as a hexamer assembled around nsp15

Identification of fragments binding to SARS-CoV-2 nsp10 reveals ligand-binding sites in conserved interfaces between nsp10 and nsp14/nsp16

IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains

Characterized monoclonal antibodies by western blot analysis and immunofluorescence. Identified multiple antibodies with unique and non-overlapping epitopes. CRediT author statement Nawneet Mishra: Conceptualization, Investigation, and Writing-Original draft preparation

Conceptualization, Investigation and Writing-Original draft preparation. Ruthmabel Boytz: Investigation Trudy N. Merritt, Lia Cardarelli, Maryna Gorelik, Filip Mihalic, Per Jemth : Investigation Shane Miersch: Project administration and supervision

Amarasinghe: Conceptualization, supervision, Writing-Reviewing and Editing, and Funding acquisition

We thank Dr. N. Krogan (UCSF) for sharing SARS-CoV-2 plasmids. We thank Ylva Ivarsson for providing the constructs, which are available at Addgene.

This work was supported by grants #2161 to GKA and SSS and #2189 to SSS from Emergent Ventures through the Thistledown Foundation (Canada) and the Mercatus Center at George Mason University and NIH grants (P01AI120943, R01AI123926 and R01AI161374 to G.K.A.; R01AI107056 to D.W.L.). This study was also supported in part by a CIHR operating grant (COVID-19 Rapid Research Funding #OV3-170649) to SSS.